Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
COVID-19 – External Monitoring Guidelines
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.
RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.
Futureproofing early phase clinical research for the next generation of investigators.
March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
-min.jpg)
.jpg)
